Yatharth Hospitals reports robust revenue growth of 39% YoY to Rs. 1,545 mn; EBITDA up by 61% YoY; PAT up by 73% YoY
National, August 19, 2023: Yatharth Hospital and Trauma Care Services Ltd, one of the leading private super specialty hospitals in Delhi NCR, announced its financial results today for the quarter ended June 30, 2023.
Financial Snapshot
| Particulars (Rs mn) | Q1FY24 | Q1FY23 | Change YoY | Q4FY23 | Change QoQ |
| Revenue from Operations | 1,545 | 1,111 | +39% | 1,438 | +7% |
| EBITDA | 414 | 257 | +61% | 385 | +8% |
| EBITDA Margin | 26.8% | 23.1% | +368 bps | 26.8% | +5 bps |
| Profit after Tax (PAT) | 190 | 110 | +73% | 173 | +10% |
| PAT Margin | 12.3% | 9.9% | +242 bps | 12.0% | +28 bps |
Key Highlights for the Quarter
- Operational Revenue was 1,545 mn, up 39% YoY and 7% QoQ
- Bed occupancy was at 51%, compared to 49% in Q4FY23 and 40% in Q1FY23
- ARPOB increased to 28,140, compared to Rs. 27,706 in Q4FY23 and Rs. 26,457 in Q1FY23
- EBITDA was 414 mn, up 61% YoY and 8% QoQ
- EBITDA margin expanded by 368 bps YoY and 5 bps QoQ to 8%
- PAT was 190 mn, up 73% YoY and 10% QoQ
Commenting on the performance, Mr. Yatharth Tyagi, Whole Time Director, Yatharth Hospital and Trauma Care Services Ltd said, “This quarter marked a pivotal landmark for our organization with a successful listing on the stock exchanges. We are pleased to report robust performance in our maiden quarter. Our revenue grew by 39% YoY to Rs. 1,545 mn, while our PAT increased by 73% YoY. During the quarter, Yatharth Hospitals registered one of the highest year-on-year growth rates in the hospital industry. Our ongoing investments reflect a strategic approach to nurturing well-balanced future growth, exemplified by ongoing expansion initiatives, both organic and inorganic.
We continue to diversify our specialty mix and introduce new specialties across all our hospitals. The past few quarters witnessed a successful ramp-up of our organ transplant and oncology treatments. We are further strengthening our specialties, offering a full suite of oncology treatments, and expanding our organ transplant operations, which is expected to drive ARPOB improvement in the upcoming quarters.
